SEARCH

SEARCH BY CITATION

Keywords:

  • chronic hepatitis B;
  • hepatitis B e antigen seroconversion;
  • hepatitis B surface antigen seroconversion;
  • hepatitis B virus DNA;
  • interferon therapy

SUMMARY. Chronic infection with the hepatitis B virus (HBV) is a major cause of worldwide morbidity and mortality. A large number of therapeutic approaches has been tried, including interferon (IFN), nucleoside analogues and immunomodulators. To date controlled clinical trials have shown that only IFN is of long-term value but many patients fail to respond to treatment. New approaches to treating patients with IFN-resistant hepatitis B are currently undergoing clinical and experimental evaluation, and it seems likely that new therapeutic agents will be available in the near future.